Skip to main content
Qaiser Bashir, MD, Oncology, Houston, TX

QaiserBashirMD

Oncology Houston, TX

Physician

Dr. Bashir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bashir's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Unit 423
    Houston, TX 77030
    Phone+1 713-794-5745
    Fax+1 713-794-4902

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Hematology and Medical Oncology, 2006 - 2009
  • University of Missouri-Columbia
    University of Missouri-ColumbiaResidency, Internal Medicine, 2003 - 2006
  • King Edward Medical University
    King Edward Medical UniversityClass of 2001

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • WA State Medical License
    WA State Medical License 2023 - 2026
  • AZ State Medical License
    AZ State Medical License 2023 - 2025
  • GA State Medical License
    GA State Medical License 2023 - 2025
  • LA State Medical License
    LA State Medical License 2023 - 2025
  • MS State Medical License
    MS State Medical License 2023 - 2025
  • OK State Medical License
    OK State Medical License 2020 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
    Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
  • Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...  
    Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Press Mentions

  • Busulfan Added to Conditioning Regimen Effective for Newly Diagnosed Myeloma
    Busulfan Added to Conditioning Regimen Effective for Newly Diagnosed MyelomaMay 20th, 2019